Market Cap 155.50M
Revenue (ttm) 52.74M
Net Income (ttm) -6.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 8.88
Profit Margin -12.51%
Debt to Equity Ratio 0.00
Volume 1,100,800
Avg Vol 882,666
Day's Range N/A - N/A
Shares Out 80.57M
Stochastic %K 41%
Beta -0.01
Analysts Strong Sell
Price Target $11.00

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial fo...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 696 9345
Address:
2 University Plaza, Suite 100, Hackensack, United States
ed29
ed29 May. 16 at 1:22 AM
0 · Reply
ToRni27
ToRni27 May. 15 at 9:20 PM
$PLX summer low was $1.32 last year. Lets see how low we can get this summer. Buy buy buy 🤑 Many longs sold out over the past 12 months as you can see if you read this board regulary. Many of them were very old longs and you don‘t see them posting anymore. Summer is always bad here so do not expect anything and comeback in fall.
0 · Reply
BryGuy29
BryGuy29 May. 15 at 5:26 PM
$RXRX this is quite common, actually. I had/have the same experience with investors of $PLX . Constant optimism despite a dying stock. Ironically, I’ve been transferring my PLX funds to RXRX, but I have much more faith in RXRX execution and management than I ever had with PLX. My lesson learned with PLX was not so much an ideal pipeline, but rather MANAGEMENT AND EXECUTION. That’s key. Good luck!!!
1 · Reply
PLX_BULLS
PLX_BULLS May. 15 at 1:46 PM
2 · Reply
milt0n
milt0n May. 15 at 12:25 PM
$PLX Another article today on the recent UK E4W approval https://www.thepharmaletter.com/biotech-news/chiesi-wins-uk-approval-for-monthly-elfabrio-dosing-in-fabry-disease
0 · Reply
milt0n
milt0n May. 15 at 12:09 PM
$PLX Well here is a little bit of good news to start your Friday off with. It appears that the UK is one of the first (if not the first) countries to implement the E4W option post-EC approval. Scotland is included as part of the UK MHRA process. This grants a marketing authorization (licence) in those countries. However, the MHRA does not determine reimbursement. Reimbursement and NHS adoption decisions are handled by health technology assessment (HTA) bodies: - NICE (National Institute for Health and Care Excellence) for England (and often influencing Wales/NI). - SMC (Scottish Medicines Consortium) for Scotland. Nonetheless this is a good sign the countries will start coming online with the new dosing. https://manufacturingchemist.com/mhra-approves-every-four-week-dosing-regimen-chiesi-fabry
4 · Reply
Artfldgr
Artfldgr May. 15 at 11:44 AM
$PLX There was a reply so I know Dror is seeing these in their inbox, as well as others now (The person starting the conversation started to loosten other tongues, be interesting if many more who been watching quiet start appearing to lend comments and put constant pressure) I agree 100%. Long-term shareholders have already experienced significant dilution over the years, and it’s hard not to feel concerned seeing additional shares proposed again. As a fellow shareholder, I’ll also be voting against this proposal. Operational progress is encouraging, but management also needs to demonstrate stronger respect for long-term investors who have continued supporting the company through difficult periods. Hopefully we start seeing a clearer path toward sustainable shareholder value creation and better alignment between management decisions and investor interests.
0 · Reply
BambooPanda
BambooPanda May. 15 at 4:27 AM
$PLX Also just checked as it has been awhile, but Elfabrio is now equal to Fabrazyme in terms of access from United Health, no step therapy/Fab fail needed. Might ask @milt0n have you got an updated review of the US insurers situation? https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/enzyme-replacement-therapy.pdf
2 · Reply
BambooPanda
BambooPanda May. 15 at 3:07 AM
$PLX From Gemini: - Oz LSDP expected completed end 2026/early 2027 - Canada public reimbursement also expected end 2026/early 2027. That said Canada has mixed private insurers and public reimbursement. So some patients may have access to Elfabrio already on private reimbursement depending on price caps the private insurere might have on per drug per year costs, where Chiesi would pay the difference until the public reimbursement is finalised, whereby the public reimbursement pays the difference.
0 · Reply
BambooPanda
BambooPanda May. 15 at 2:34 AM
$PLX Small note, 2H 2026, we very likely have; - The FLY dose ranging part 1 PK data due out on the pediatric study - The RISE topline PK/PD & Safety results of the Japanese study. The PK/PD & Safety data is what the Japanese regulators use for assessment from a bridging study. With filing to the Japanese, the 2nd biggest country Fabry market in the world in early 2027. So while we are still on the 15% royalty tier, Chiesi is still spending good money about 10-15M per year on these smaller 2 trials, let alone the millions it costs per country to go through all the filing and reimbursement processes. Management initially stated after an initial number of years there would be a rebalancing on the amount of royalties owed. One assumes that this rebalancing would be happening once the vast majority of these cost are out of the way. As we at least know, reimbursement Oz & Canada still ongoing. Once Japan is done, that should be the final key market to settle that.
1 · Reply
Latest News on PLX
Protalix BioTherapeutics Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 2 days ago

Protalix BioTherapeutics Earnings Call Transcript: Q1 2026


Protalix BioTherapeutics Earnings Call Transcript: Q4 2025

Mar 18, 2026, 8:00 AM EDT - 2 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2025


Protalix BioTherapeutics Letter to Stockholders

Jan 5, 2026, 6:50 AM EST - 4 months ago

Protalix BioTherapeutics Letter to Stockholders


Protalix BioTherapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 8:00 AM EST - 6 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2025


Protalix BioTherapeutics to Present at Investor Summit Virtual

Sep 11, 2025, 10:55 AM EDT - 8 months ago

Protalix BioTherapeutics to Present at Investor Summit Virtual


Protalix BioTherapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 9 months ago

Protalix BioTherapeutics Earnings Call Transcript: Q2 2025


Protalix appoints Gilad Mamlok as CFO

2025-07-21T10:55:33.000Z - 10 months ago

Protalix appoints Gilad Mamlok as CFO


Protalix added to Russell 3000, Russell 2000 Indexes

2025-06-30T14:45:15.000Z - 11 months ago

Protalix added to Russell 3000, Russell 2000 Indexes


Protalix BioTherapeutics Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q1 2025


Protalix files $100M mixed securities shelf

2025-04-28T21:05:49.000Z - 1 year ago

Protalix files $100M mixed securities shelf


Protalix BioTherapeutics Earnings Call Transcript: Q4 2024

Mar 17, 2025, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2024


Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Dec 23, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders


Protalix BioTherapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2024


Protalix BioTherapeutics Earnings Call Transcript: Q2 2024

Aug 14, 2024, 8:30 AM EDT - 1 year ago

Protalix BioTherapeutics Earnings Call Transcript: Q2 2024


Protalix BioTherapeutics Transcript: Investor Day 2024

Jun 26, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Transcript: Investor Day 2024


Protalix BioTherapeutics Earnings Call Transcript: Q1 2024

May 10, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q1 2024


Protalix BioTherapeutics Earnings Call Transcript: Q4 2023

Mar 14, 2024, 8:30 AM EDT - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q4 2023


Protalix BioTherapeutics Issues 2024 Letter to Stockholders

Dec 26, 2023, 6:50 AM EST - 2 years ago

Protalix BioTherapeutics Issues 2024 Letter to Stockholders


Protalix BioTherapeutics Earnings Call Transcript: Q3 2023

Nov 6, 2023, 8:30 AM EST - 2 years ago

Protalix BioTherapeutics Earnings Call Transcript: Q3 2023


ed29
ed29 May. 16 at 1:22 AM
0 · Reply
ToRni27
ToRni27 May. 15 at 9:20 PM
$PLX summer low was $1.32 last year. Lets see how low we can get this summer. Buy buy buy 🤑 Many longs sold out over the past 12 months as you can see if you read this board regulary. Many of them were very old longs and you don‘t see them posting anymore. Summer is always bad here so do not expect anything and comeback in fall.
0 · Reply
BryGuy29
BryGuy29 May. 15 at 5:26 PM
$RXRX this is quite common, actually. I had/have the same experience with investors of $PLX . Constant optimism despite a dying stock. Ironically, I’ve been transferring my PLX funds to RXRX, but I have much more faith in RXRX execution and management than I ever had with PLX. My lesson learned with PLX was not so much an ideal pipeline, but rather MANAGEMENT AND EXECUTION. That’s key. Good luck!!!
1 · Reply
PLX_BULLS
PLX_BULLS May. 15 at 1:46 PM
2 · Reply
milt0n
milt0n May. 15 at 12:25 PM
$PLX Another article today on the recent UK E4W approval https://www.thepharmaletter.com/biotech-news/chiesi-wins-uk-approval-for-monthly-elfabrio-dosing-in-fabry-disease
0 · Reply
milt0n
milt0n May. 15 at 12:09 PM
$PLX Well here is a little bit of good news to start your Friday off with. It appears that the UK is one of the first (if not the first) countries to implement the E4W option post-EC approval. Scotland is included as part of the UK MHRA process. This grants a marketing authorization (licence) in those countries. However, the MHRA does not determine reimbursement. Reimbursement and NHS adoption decisions are handled by health technology assessment (HTA) bodies: - NICE (National Institute for Health and Care Excellence) for England (and often influencing Wales/NI). - SMC (Scottish Medicines Consortium) for Scotland. Nonetheless this is a good sign the countries will start coming online with the new dosing. https://manufacturingchemist.com/mhra-approves-every-four-week-dosing-regimen-chiesi-fabry
4 · Reply
Artfldgr
Artfldgr May. 15 at 11:44 AM
$PLX There was a reply so I know Dror is seeing these in their inbox, as well as others now (The person starting the conversation started to loosten other tongues, be interesting if many more who been watching quiet start appearing to lend comments and put constant pressure) I agree 100%. Long-term shareholders have already experienced significant dilution over the years, and it’s hard not to feel concerned seeing additional shares proposed again. As a fellow shareholder, I’ll also be voting against this proposal. Operational progress is encouraging, but management also needs to demonstrate stronger respect for long-term investors who have continued supporting the company through difficult periods. Hopefully we start seeing a clearer path toward sustainable shareholder value creation and better alignment between management decisions and investor interests.
0 · Reply
BambooPanda
BambooPanda May. 15 at 4:27 AM
$PLX Also just checked as it has been awhile, but Elfabrio is now equal to Fabrazyme in terms of access from United Health, no step therapy/Fab fail needed. Might ask @milt0n have you got an updated review of the US insurers situation? https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/enzyme-replacement-therapy.pdf
2 · Reply
BambooPanda
BambooPanda May. 15 at 3:07 AM
$PLX From Gemini: - Oz LSDP expected completed end 2026/early 2027 - Canada public reimbursement also expected end 2026/early 2027. That said Canada has mixed private insurers and public reimbursement. So some patients may have access to Elfabrio already on private reimbursement depending on price caps the private insurere might have on per drug per year costs, where Chiesi would pay the difference until the public reimbursement is finalised, whereby the public reimbursement pays the difference.
0 · Reply
BambooPanda
BambooPanda May. 15 at 2:34 AM
$PLX Small note, 2H 2026, we very likely have; - The FLY dose ranging part 1 PK data due out on the pediatric study - The RISE topline PK/PD & Safety results of the Japanese study. The PK/PD & Safety data is what the Japanese regulators use for assessment from a bridging study. With filing to the Japanese, the 2nd biggest country Fabry market in the world in early 2027. So while we are still on the 15% royalty tier, Chiesi is still spending good money about 10-15M per year on these smaller 2 trials, let alone the millions it costs per country to go through all the filing and reimbursement processes. Management initially stated after an initial number of years there would be a rebalancing on the amount of royalties owed. One assumes that this rebalancing would be happening once the vast majority of these cost are out of the way. As we at least know, reimbursement Oz & Canada still ongoing. Once Japan is done, that should be the final key market to settle that.
1 · Reply
ed29
ed29 May. 15 at 1:58 AM
0 · Reply
ZacksSCR
ZacksSCR May. 14 at 8:57 PM
$PLX: Chiesi Milestone Received https://buff.ly/LsI9s9O
0 · Reply
GCooter
GCooter May. 14 at 7:57 PM
$PLX above $2. You guys hard?
2 · Reply
TheMotleyMonk
TheMotleyMonk May. 14 at 7:13 PM
$PLX What really bothers me is the deception involved with Wainwrong's 2026 target price for PLX. Who in their right mind, after reading the most recent quarterly report, believes that on December 31, 2026, PLX will be selling for $11? Wainwrong has been wrong on so many estimates, it's laughable. Don't get me wrong about Wainwrong -- I sure hope he's Wainright!
1 · Reply
PRX102
PRX102 May. 14 at 6:08 PM
$PLX when will we get to the next royalty tier ? 15% doesn’t move the revenue needle much….
0 · Reply
Artfldgr
Artfldgr May. 14 at 5:23 PM
$PLX Dror posted his face book news of the progress they are making, and someone posted this in the thread: Congratulations to the Protalix team on the reported operational progress, including the Chiesi milestone and continued advancement of PRX-115. As a long-term shareholder, I would welcome a clearer discussion of shareholder value creation. While the company continues to report operational progress, the share price has not reflected that progress over a long period, and dilution remains a real concern for investors who have supported the company through multiple stages. That concern is especially relevant given Proposal 3, which asks shareholders to approve an additional 3.5 million shares under the company’s stock incentive plan. Operational progress matters, but owners also need to see capital discipline, recurring revenue growth, and a credible path for that progress to translate into sustained market recognition.
4 · Reply
Yomama1111111
Yomama1111111 May. 14 at 5:13 PM
0 · Reply
RunningRobert1
RunningRobert1 May. 14 at 2:04 PM
$PLX Protalix Biotherapeutics PLX 1Q 2026 Quarterly Summary 14May2026 https://youtu.be/1MMxm_7HsoA Sold my position, but I dont think its a bad stock, I just think its going to be flat for the rest of the year if they are within the guidance, def will follow it to see, and might come back to it in 2027 for the gout drug
2 · Reply
Ron_Burn
Ron_Burn May. 14 at 8:26 AM
$PLX oversold with positive news. she tried breaking out of the downtrend during the day but was knocked back down, Might see some action in the next few days
2 · Reply
zoomlik
zoomlik May. 14 at 3:37 AM
$PLX Elfabrio adoption has been slower than I had hoped for. But, with time, share price goes up
1 · Reply
Ado97
Ado97 May. 13 at 9:44 PM
$PLX That the result of the great drug Elfabrio for Protalix would only be a future share buyback, which is out of sight? Sad.
0 · Reply
BryGuy29
BryGuy29 May. 13 at 9:07 PM
$PLX still uninvestable.
2 · Reply